Company Releases Data From Open Label Trial of Experimental Fragile X Syndrome Treatment
7raysmarketing / Pixabay

Company Releases Data From Open Label Trial of Experimental Fragile X Syndrome Treatment

According to a story from globenewswire.com, the drug company Zynerba Pharmaceuticals, Inc. has announced that the data from its phase 2 open label trial has been officially published. This clinical…

Continue Reading Company Releases Data From Open Label Trial of Experimental Fragile X Syndrome Treatment

DNA Sequencing Took Years, Now it Takes Hours; As a Result, Researchers Have Discovered The Cause of Four Rare Diseases

Researchers at the University of Tokyo have discovered that one segment of DNA is responsible for four rare diseases. As reported in Science Daily, the university team also believes that…

Continue Reading DNA Sequencing Took Years, Now it Takes Hours; As a Result, Researchers Have Discovered The Cause of Four Rare Diseases

New Technology for Diagnosing Rare Conditions by Photograph May Foster Employment Discrimination?

As discussed in a recent article on PatientWorthy the FDNA has recently developed a new kind of algorithm which can diagnose rare genetic conditions such as Angelman syndrome, Williams syndrome, and Fragile X syndrome using…

Continue Reading New Technology for Diagnosing Rare Conditions by Photograph May Foster Employment Discrimination?

A Group of Disorders Share Similarities in Their DNA 3D Folding Patterns, Researchers Say

Researchers at the University of Pennsylvania have studied the genetics of a class of neurological disorders that includes Huntington’s disease and Fragile X Syndrome. They found that there were similarities…

Continue Reading A Group of Disorders Share Similarities in Their DNA 3D Folding Patterns, Researchers Say
An Experimental Treatment for Fragile X and Angelman Syndromes Gets Fast Track Designation
Source: Pixabay

An Experimental Treatment for Fragile X and Angelman Syndromes Gets Fast Track Designation

According to a story from pharmiweb.com, the pharmaceutical company Ovid Therapeutics announced recently that the U.S. Food and Drug Administration (FDA) has given its drug candidate OV101 Fast Track designation…

Continue Reading An Experimental Treatment for Fragile X and Angelman Syndromes Gets Fast Track Designation